Author: Benzinga Newsdesk | September 22, 2025 04:12pm
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.33) by 25.75 percent. This is a 30 percent increase over losses of $(0.60) per share from the same period last year.